|
1
|
Ebb D, Meyers P, Grier H, Bernstein M,
Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal
GP, et al: Phase II trial of trastuzumab in combination with
cytotoxic chemotherapy for treatment of metastatic osteosarcoma
with human epidermal growth factor receptor 2 overexpression: A
report from the children's oncology group. J Clin Oncol.
30:2545–2551. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li J, Guo Z, Wang Z, Fan H and Fu J: Does
microwave ablation of the tumor edge allow for joint-sparing
surgery in patients with osteosarcoma of the proximal tibia? Clin
Orthop Relat Res. 473:3204–3211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bajpai J, Gamanagatti S, Sharma MC, Kumar
R, Vishnubhatla S, Khan SA, Rastogi S, Malhotra A and Bakhshi S:
Noninvasive imaging surrogate of angiogenesis in osteosarcoma.
Pediatr Blood Cancer. 54:526–531. 2010.PubMed/NCBI
|
|
4
|
Bacci G, Ferrari S, Longhi A, Picci P,
Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, et
al Italian Sarcoma Group/Scandinavian Sarcoma Group, : High dose
ifosfamide in combination with high dose methotrexate, adriamycin
and cisplatin in the neoadjuvant treatment of extremity
osteosarcoma: Preliminary results of an Italian Sarcoma
Group/Scandinavian Sarcoma Group pilot study. J Chemother.
14:198–206. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang X, Ning Y, Yang L, Liu H, Wu C, Wang
S and Guo X: Diagnostic value of circulating microRNAs for
osteosarcoma in Asian populations: A meta-analysis. Clin Exp Med.
17:175–183. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen R, Li X, He B and Hu W: MicroRNA-410
regulates autophagy-related gene ATG16L1 expression and enhances
chemosensitivity via autophagy inhibition in osteosarcoma. Mol Med
Rep. 15:1326–1334. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shang Y, Wang LQ, Guo QY and Shi TL:
MicroRNA-196a overexpression promotes cell proliferation and
inhibits cell apoptosis through PTEN/Akt/FOXO1 pathway. Int J Clin
Exp Pathol. 8:2461–2472. 2015.PubMed/NCBI
|
|
8
|
Han K, Zhou Y, Gan ZH, Qi WX, Zhang JJ,
Fen T, Meng W, Jiang L, Shen Z and Min DL: p21-activated kinase 7
is an oncogene in human osteosarcoma. Cell Biol Int. 38:1394–1402.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang X, Ma W, Cui J, Yao H, Zhou H, Ge Y,
Xiao L, Hu X, Liu BH, Yang J, et al: Regulation of p21 by TWIST2
contributes to its tumor-suppressor function in human acute myeloid
leukemia. Oncogene. 34:3000–3010. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pappo AS, Vassal G, Crowley JJ, Bolejack
V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon
AP, et al: A phase 2 trial of R1507, a monoclonal antibody to the
insulin-like growth factor-1 receptor (IGF-1R), in patients with
recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial
sarcoma, and other soft tissue sarcomas: Results of a Sarcoma
Alliance for Research Through Collaboration study. Cancer.
120:2448–2456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kudawara I, Aoki Y, Ueda T, Araki N, Naka
N, Nakanishi H, Matsumine A, Ieguchi M, Mori S, Myoui A, et al:
Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide,
doxorubicin, cisplatin and high-dose methotrexate in non-metastatic
osteosarcoma of the extremities: A phase II trial in Japan. J
Chemother. 25:41–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grignani G, Palmerini E, Ferraresi V,
D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y,
Sangiolo D, Marchesi E, et al Italian Sarcoma Group, : Sorafenib
and everolimus for patients with unresectable high-grade
osteosarcoma progressing after standard treatment: A non-randomised
phase 2 clinical trial. Lancet Oncol. 16:98–107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
den Hengst WA, Hendriks JM, Balduyck B,
Rodrigus I, Vermorken JB, Lardon F, Versteegh MI, Braun J,
Gelderblom H, Schramel FM, et al: Phase II multicenter clinical
trial of pulmonary metastasectomy and isolated lung perfusion with
melphalan in patients with resectable lung metastases. J Thorac
Oncol. 9:1547–1553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fan B, Jiao BH, Fan FS, Lu SK, Song J, Guo
CY, Yang JK and Yang L: Downregulation of miR-95-3p inhibits
proliferation, and invasion promoting apoptosis of glioma cells by
targeting CELF2. Int J Oncol. 47:1025–1033. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Z, He R, Xia H, Wei YU and Wu S:
MicroRNA-101 has a suppressive role in osteosarcoma cells through
the targeting of c-FOS. Exp Ther Med. 11:1293–1299. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu M, Xie Y, Sheng W, Miao J and Yang J:
Adenovirus-mediated ING4 gene transfer in osteosarcoma suppresses
tumor growth via induction of apoptosis and inhibition of tumor
angiogenesis. Technol Cancer Res Treat. 14:369–378. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yong ST and Wang XF: A novel,
non-apoptotic role for Scythe/BAT3: A functional switch between the
pro- and anti-proliferative roles of p21 during the cell cycle.
PLoS One. 7:e380852012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ye J, Yao Y, Song Q, Li S, Hu Z, Yu Y, Hu
C, Da X, Li H, Chen Q, et al: Up-regulation of miR-95-3p in
hepatocellular carcinoma promotes tumorigenesis by targeting p21
expression. Sci Rep. 6:340342016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim BG, Lee JH, Yasuda J, Ryoo HM and Cho
JY: Phospho-Smad1 modulation by nedd4 E3 ligase in BMP/TGF-β
signaling. J Bone Miner Res. 26:1411–1424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Navid F, Letterio JJ, Yeung CL, Pegtel M
and Helman LJ: Autocrine transforming growth factor-beta growth
pathway in murine osteosarcoma cell lines associated with inability
to affect phosphorylation of retinoblastoma protein. Sarcoma.
4:93–102. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li F, Li S and Cheng T: TGF-β1 promotes
osteosarcoma cell migration and invasion through the
miR-143-versican pathway. Cell Physiol Biochem. 34:2169–2179. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chow LT: Giant cell rich osteosarcoma
revisited-diagnostic criteria and histopathologic patterns, Ki67,
CDK4, and MDM2 expression, changes in response to bisphosphonate
and denosumab treatment. Virchows Arch. 468:741–755. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Benassi MS, Molendini L, Gamberi G,
Ragazzini P, Sollazzo MR, Merli M, Asp J, Magagnoli G, Balladelli
A, Bertoni F, et al: Alteration of pRb/p16/cdk4 regulation in human
osteosarcoma. Int J Cancer. 84:489–493. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang C, Zhao Y and Zeng B: Enhanced
chemosensitivity by simultaneously inhibiting cell cycle
progression and promoting apoptosis of drug-resistant osteosarcoma
MG63/DXR cells by targeting cyclin D1 and Bcl-2. Cancer Biomark.
12:155–167. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Ni J, Yi S, Song D and Ding M:
Protein inhibitor of activated STAT xα depresses cyclin D and
cyclin D kinase, and contributes to the inhibition of osteosarcoma
cell progression. Mol Med Rep. 13:1645–1652. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hwang SJ, Lee HW, Kim HR, Song HJ, Lee DH,
Lee H, Shin CH, Joung JG, Kim DH, Joo KM, et al: Overexpression of
microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma
through downregulation of cyclin D1. Oncotarget. 6:20434–20448.
2015. View Article : Google Scholar : PubMed/NCBI
|
